Trial watch: anticancer vaccination with dendritic cells

被引:2
作者
Borges, Francisca [1 ]
Laureano, Raquel S. [1 ]
Vanmeerbeek, Isaure [1 ]
Sprooten, Jenny [1 ]
Demeulenaere, Octavie [1 ]
Govaerts, Jannes [1 ]
Kinget, Lisa [1 ]
Saraswat, Saurabh [1 ]
Beuselinck, Benoit [2 ]
De Vleeschouwer, Steven [3 ,4 ,5 ]
Clement, Paul [6 ]
De Smet, Frederik [7 ,8 ,9 ]
Sorg, Ruediger V. [10 ]
Datsi, Angeliki [10 ]
Vigneron, Nathalie [11 ,12 ]
Naulaerts, Stefan [1 ]
Garg, Abhishek D. [1 ]
机构
[1] Katholieke Univ Leuven, Dept Cellular & Mol Med, Cell Stress & Immun, Leuven, Belgium
[2] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Med Oncol, Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Neurosci, Res Grp Expt Neurosurg & Neuroanat, Leuven, Belgium
[4] Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium
[5] Katholieke Univ Leuven, Leuven Brain Inst LBI, Leuven, Belgium
[6] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium
[7] Katholieke Univ Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Unit, Lab Precis Canc Med, Leuven, Belgium
[8] Katholieke Univ Leuven, Leuven Inst Single Cell Om LISCO, Leuven, Belgium
[9] Katholieke Univ Leuven, Leuven Canc Inst, Leuven, Belgium
[10] Heinrich Heine Univ Hosp, Dusseldorf, Germany
[11] Univ Louvain, Ludwig Inst Canc Res, Brussels, Belgium
[12] Univ Louvain, Cellular Genet Unit, Brussels, Belgium
来源
ONCOIMMUNOLOGY | 2024年 / 13卷 / 01期
关键词
Antigen cross-presentation; clinical trial; DAMPs; dendritic cells; immune checkpoint blockers; T cell priming; TAAs; tumor-infiltrating lymphocytes; CANCER-IMMUNOTHERAPY; SIPULEUCEL-T; ANTIGEN; RESPONSES; VACCINES; ELECTROFUSION; PROGENITORS; INDUCTION; IMMUNITY; DIFFERENTIATION;
D O I
10.1080/2162402X.2024.2412876
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology.
引用
收藏
页数:16
相关论文
共 242 条
  • [1] Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
    Abbaspour, Maryam
    Akbari, Vajihe
    [J]. EXPERT REVIEW OF VACCINES, 2022, 21 (03) : 337 - 353
  • [2] Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
    Adamik, Juraj
    Munson, Paul V.
    Maurer, Deena M.
    Hartmann, Felix J.
    Bendall, Sean C.
    Arguello, Rafael J.
    Butterfield, Lisa H.
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [3] Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial
    Adams, Alexandra M.
    Carpenter, Elizabeth L.
    Clifton, Guy T.
    Vreeland, Timothy J.
    Chick, Robert C.
    O'Shea, Anne E.
    McCarthy, Patrick M.
    Bohan, Phillip M. Kemp
    Hickerson, Annelies T.
    Valdera, Franklin A.
    Tiwari, Ankur
    Hale, Diane F.
    Hyngstrom, John R.
    Berger, Adam C.
    Jakub, James W.
    Sussman, Jeffrey J.
    Shaheen, Montaser F.
    Yu, Xianzhong
    Wagner, Thomas E.
    Faries, Mark B.
    Peoples, George E.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (03) : 697 - 705
  • [4] Genetic models of human and mouse dendritic cell development and function
    Anderson, David A., III
    Dutertre, Charles-Antoine
    Ginhoux, Florent
    Murphy, Kenneth M.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2021, 21 (02) : 101 - 115
  • [5] Evasion before invasion: Pre-cancer immunosurveillance
    Angelova, Mihaela
    Mascaux, Celine
    Galon, Jerome
    [J]. ONCOIMMUNOLOGY, 2021, 10 (01):
  • [6] Clinical use of dendritic cells for cancer therapy
    Anguille, Sebastien
    Smits, Evelien L.
    Lion, Eva
    van Tendeloo, Viggo F.
    Berneman, Zwi N.
    [J]. LANCET ONCOLOGY, 2014, 15 (07) : E257 - E267
  • [7] Arun J, 2023, Georgian Med News, P105
  • [8] Classical DC2 subsets and monocyte-derived DC: Delineating the developmental and functional relationship
    Backer, Ronald A.
    Probst, Hans Christian
    Clausen, Bjoern E.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 (03)
  • [9] Leptin/lipopolysaccharide-treated dendritic cell vaccine improved cellular immune responses in an animal model of breast cancer
    Basirjafar, Pedram
    Zandvakili, Raziyeh
    Masoumi, Javad
    Zainodini, Nahid
    Taghipour, Zahra
    Khorramdelazad, Hossein
    Yousefi, Soheila
    Tavakoli, Tayyebeh
    Vatanparast, Mahboobeh
    Safdel, Sepehr
    Gheitasi, Mahsa
    Ayoobi, Fatemeh
    Naseri, Bahar
    Jafarzadeh, Abdollah
    [J]. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2024, 46 (01) : 73 - 85
  • [10] Induction of a CD8(+) cytotoxic T lymphocyte response by cross-priming requires cognate CD4(+) T cell help
    Bennett, SRM
    Carbone, FR
    Karamalis, F
    Miller, JFAP
    Heath, WR
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) : 65 - 70